Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from GlucoTrack ( (GCTK) ) is now available.
On February 4, 2025, Glucotrack, Inc. entered a securities purchase agreement with institutional investors to offer and sell approximately 2.6 million shares of its common stock at $1.15 per share. The offering is expected to generate gross proceeds of approximately $3.03 million, which the company plans to use for working capital and general corporate purposes. The closing of the offering is anticipated by February 5, 2025, with Dawson James Securities, Inc. acting as the placement agent. The agreement restricts the company from issuing additional shares or entering certain transactions for 30 days following the offering’s closure, while directors and executives will adhere to a 180-day lock-up period.
More about GlucoTrack
Glucotrack, Inc. is a medical technology company focused on the design, development, and commercialization of novel technologies for individuals with diabetes. The company is currently working on a long-term implantable continuous blood glucose monitoring system, which features a sensor longevity of three years and minimal calibration requirements.
YTD Price Performance: -89.14%
Average Trading Volume: 3,146,623
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $177.3M
For an in-depth examination of GCTK stock, go to TipRanks’ Stock Analysis page.
